Page Redirect Alert
The link you are about to visit does not belong to this site, please pay attention to your account security.
https://cts.businesswire.com/ct/CT?id=smartlink&url=https://ascopubs.org/doi/pdf/10.1200/JCO.2023.41.16_suppl.e14583#:~:text=AVM0703%2C%20an%20immunomodulatory%20drug%2C%20mobilizes%20bispecific%20and%20i-TCR,%2B%2024%20hours%20later%2C%20with%20no%20additional%20toxicities.&esheet=53514448&newsitemid=20230809463056&lan=en-US&anchor=potent neo-adjuvant&index=15&md5=3e93fa0d59c670c7b804709377d61b3e
